Design and synthesis of non-TZD peroxisome proliferator-activated receptor γ (PPARγ) modulator

Thiazolidinediones (TZDs) are an important class of compound used for the treatment of type 2 diabetes, targeting the peroxisome proliferator-activated receptor γ (PPARγ). Drug-induced hepatotoxicity, edema, and weight gain are the main concerns associated with TZDs. It was unclear whether the sid...

Full description

Bibliographic Details
Main Authors: Deka, N., Uravane, M., Anthony, J., Bhumra, S., Nair, A., B-Rao, C., Patel, Dharmeshkumar, Sivaramakrishnan, H.
Format: Journal Article
Published: Birkhaeuser Science 2014
Online Access:http://hdl.handle.net/20.500.11937/63091
Description
Summary:Thiazolidinediones (TZDs) are an important class of compound used for the treatment of type 2 diabetes, targeting the peroxisome proliferator-activated receptor γ (PPARγ). Drug-induced hepatotoxicity, edema, and weight gain are the main concerns associated with TZDs. It was unclear whether the side effects observed are target mediated or compound mediated, but most of the TZDs activate PPARγ. This obliged developing of a new diverse class of ligands as antihyperglycemic agents including non-TZD PPAR ligands that could be highly effective, safe, and devoid of side effects. Here, we report the design and synthesis of N-(5-chloro-6-((1-phenylpiperidin-4-yl)oxy)pyridin-3-yl) benzenesulfonamide derivatives as non-TZD PPARγ modulators. © Springer Science+Business Media 2013.